Intestinal Anti-infective Market: Rising Awareness among the People and Favorable Government Initiatives for the Treatment of Infectious Diseases is Projected to Boost the Market Growth

A substance or an agent that aids the immune system by inhibiting infective micro-organisms by inferring with different mechanisms such as cell wall synthesis or DNA synthesis or by slowing their glow. The infection of intestine is known as intestinal infection. Intestinal infection are bacterial, viral or parasitic infections that cause inflammation of gastrointestinal tract that is gastroenteritis. The intestinal infection shows symptoms that includes vomiting, diarrhea and abdominal pain, to treat the intestinal infection anti-infective agents are used.

The anti-infective agents kills or suppress the infection causing organism from invading the host organism, such infections are caused by micro-organisms such as fungi, bacteria or viruses. The infection may result from poor hygiene or consuming contaminated food or water. The infection which are caused by food are also called as food poisoning.

Download PDF Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14111

Rising prevalence of intestinal infections and resistance to anti-infective agents are the key factors driving the market of intestinal anti-infectives globally. In addition, rising awareness among the people and favorable government initiatives for the treatment of infectious diseases is projected to boost the market growth of intestinal anti-infectives market. The expiration of patent for various drugs increase the generic competition in market. The rising demand for extensive R&D efforts to develop new high potency drugs as resistance has been developed by micro-organisms for the drugs is one of the major factor stimulate the growth of global intestinal anti-infective agents market.

The global market of intestinal anti-infectives is classified on the basis of product type, distribution channel and geography. The product type segment is further divided as anti-fungal, anti-viral and anti-bacterial depending upon infection caused by type of micro-organism. The product class includes chemical nature of drug and there mechanism to kill the microbes. The drugs kill the microbes by interfering with the cell wall of the micro-organisms and interfering with protein synthesis. anti-fungal agents are further segmented as Allylamines, Azoles, Polyene, and Macrolides derivatives, these drugs treat the infection caused by fungus.

The anti-bacterial segment is further divided in Aminoglycosides, Carbapenems, Cephalosporin, Macrolides, Penicillins, Quinolones, Sulfonamides, and Tetracyclines. These are antibiotics that kills the bacteria by different mechanism. The anti-viral agents are Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, and Protease Inhibitors. These drugs inhibit the nucleic acid synthesis kill or suppress the infective organisms

Geographically the global market for intestinal anti-infective is segmented as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Increasing consumption of fast food in North America and changing lifestyle are some of the prime factors driving the growth of intestinal infections in the region, followed by Europe. Thus, owing to the above mentioned factors North America and Europe dominates the global intestinal anti-infectives market. The emerging economies are also promising to show high growth potential in the global intestinal anti-infectives market. Factors such as rising government initiatives and increasing patient pool in countries such as India due to growing awareness supports the growth in Asia Pacific market.

There are also some common trends that affect the market such as generic competition, price issues, and reimbursement issues. Currently, both antifungal and antibacterial segments have experienced heavy generic competition, limiting growth despite introduction of new products to each market segment. Concerns in the antibacterial segment over resistance have resulted in additional funding for new treatments specifically targeting resistant bacteria.

Browse Full Research Report: http://www.transparencymarketresearch.com/intestinal-antiinfective-market.html

Although there seems to be a solution on the surface, many developers are reluctant to follow this development path. Abbott Laboratories, AstraZeneca plc, Bristol-Myers Squibb, Gilead Science, GlaxoSmithKline, Johnson & Johnson, Novartis and Pfizer are some of the key players having presence in the global intestinal anti-infectives market.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.